Document is current
Any future updates will be listed below
-
Authors
Lissemore, Jennifer I. https://orcid.org/0000-0003-0192-1453
Chaiken, Anna
Cherian, Kirsten N. https://orcid.org/0000-0002-6058-0081
Buchanan, Derrick https://orcid.org/0000-0003-4478-2844
Espil, Flint
Keynan, Jackob N.
Sridhar, Malvika https://orcid.org/0009-0005-0750-4329
Rolle, Camarin E.
Saggar, Manish https://orcid.org/0000-0002-5307-2249
Keller, Corey J. https://orcid.org/0000-0003-0529-3490
Williams, Nolan R. https://orcid.org/0000-0003-4368-3203
- License Information
-
More Information
Article History
Received: 7 September 2024
Accepted: 17 June 2025
First Online: 24 July 2025
Competing interests
: C.J.K. holds equity in Alto Neuroscience, Inc and is a consultant for Flow Neuroscience. N.R.W. is a named inventor on Stanford-owned intellectual property relating to magnesium–ibogaine; he has served on scientific advisory boards for Otsuka, NeuraWell, Magnus Medical, Soneira and Nooma as a paid adviser, and he has equity/stock options in NeuraWell, Soneira and Nooma. N.R.W. and J.I.L. are listed as inventors on US provisional patent applications that cover some of the aspects reported here (63/804,501). The remaining authors declare no competing interests.
